Lyra Therapeutics Inc. Logo

Lyra Therapeutics Inc.

OTC

Currency in USD
0.5200
-0.05 (-8.76%)

Real-time Data

01:30 PM

Day's Range

0.3622
0.5200

52 wk Range

0.3001
8.75
Loading

Key Statistics

Symbol

LYRA

Name

Lyra Therapeutics Inc.

Currency

USD

Exchange

OTC

High

0.51999998

Low

0.36219999

Open

‪0.4501‬

Last

‪0.5200‬

Market Cap

922.93K

Volume

11.77K

Average Volume

25.88K

Dividend Yield

‪0.00%‬

Change

-0.05

Percent Change

-8.76

Timestamp

2026-07-17

Close

0.51999998

Today Range Start

‪0.3622‬

Today Range End

‪0.5200‬

52 Week Range Start

‪0.3001‬

52 Week Range End

‪8.75‬

Type

Stocks

Country

United States

Compliance - LYRA - Lyra Therapeutics Inc.

Compliance

Status

NON_COMPLIANT

Report Date

2025-02-19

Business Screen

NON_COMPLIANT

Financial Screen

NON_COMPLIANT

Compliant Revenue

‪4.00%‬

Non Compliant Revenue

‪96.00%‬

Questionable Revenue

‪0.00%‬

Securities To Market Cap Ratio

‪50.00%‬

Debt To Market Cap Ratio

‪1.20%‬

Historical Data - LYRA - Lyra Therapeutics Inc.

Historical Data

TimeOpenHighLowCloseVolume

No data available

Market Cap - LYRA - Lyra Therapeutics Inc.

Market Cap

2026-07-17

922.93K

2026-07-16

1.01M

2026-07-15

927.19K

2026-07-14

749.26K

2026-07-13

851.94K

2026-07-10

957.37K

2026-07-09

958.34K

2026-07-08

905.18K

2026-07-07

1.06M

2026-07-06

1.05M

Profile - LYRA - Lyra Therapeutics Inc.

Profile

Mic Code

PINX

Sector

Healthcare

Industry

Biotechnology

Employees

27


Lyra Therapeutics Inc. is a biopharmaceutical company focusing on developing therapies for patients with ear, nose, and throat (ENT) diseases. The company's primary purpose is to address the unmet needs in the treatment of chronic rhinosinusitis (CRS) and related conditions by utilizing an innovative polymer-based platform, XTreo, which offers sustained delivery of medications directly to the affected area. This strategic approach aims to enhance treatment efficacy, reduce systemic side effects, and improve patient outcomes. Lyra's work primarily impacts the healthcare sector, particularly within the specialty pharmaceuticals industry. The significance of Lyra Therapeutics in the market lies in its potential to transform ENT disease management with novel, localized therapies that address the root cause of the ailment, positioning itself as a leader in the evolution of targeted, long-term ENT treatments.

Profile Details

Type

Common Stock

Ceo

Dr. Maria Palasis Ph.D.

Address

480 Arsenal Way

City

Watertown

State

MA

Zip

02472

Country

United States

Phone

617 393 4600

Related news

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.
Lyra Therapeutics Inc. (LYRA - OTC) Price Today | UA Finance